Sarepta schedules conference call to update investors on eteplirsen; shares slump 6%

• Sarepta Therapeutics (SRPT -5.5%) appears to have investors a bit spooked over its conference call scheduled for October 1 at 7:00 am ET to discuss recent data from the Phase 2b study of eteplirsen in Duchenne muscular dystrophy. Any bad news will send the stock tumbling.  Down volume at present is light, less than 500K shares.
• DMD-related tickers: (CATB -8.3%)(BMRN -1.6%)(FGEN -4%)(PFE -0.8%) (MRNA +1.4%)(CAPR -1.8%)(SMMT -1%)(PTCT -3.7%) (OTCPK:SPHDF)